Treatment Of Sepsis With PCSK9 And LDLR Modulators
Application
US20260078378A1
Kind: A1
Mar 19, 2026
Inventors
Julie Horowitz, Luca Andrea Lotta, Manuel Allen Revez Ferreira, Amy Damask, Charles Paulding, Garen Manvelian, Michael Cantor, Aris Baras
Abstract
The present disclosure provides methods of treating subjects having sepsis, SIRS, septic shock, and/or MODS, methods of identifying subjects having an increased risk of developing sepsis, SIRS, septic shock, and/or MODS, and methods of detecting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and/or Low Density Lipoprotein Receptor (LDLR) variant nucleic acid molecules and variant polypeptides.
CPC Classifications
C12N 15/1137
A61P 31/00
C12N 9/22
C12N 15/11
C12Q 1/6883
C12N 2310/20
C12Q 2600/156
Filing Date
2025-07-01
Application No.
19256467